Moderna Unveils Current Pricing for COVID-19 Vaccine Supply Deals

Moderna is offering its COVID-19 vaccine candidate at $32 to $37 per dose for smaller-scale supply agreements, the company’s CEO Stéphane Bancel said Wednesday.

In an investor call, Bancel said that the company is currently in discussions over larger deals for the experimental vaccine, mRNA-1273 and plans to charge lower per-dose prices for higher volumes, though he didn’t give specifics.

“We are working with governments around the world and others to ensure a vaccine is accessible regardless of ability to pay,” he said. “During the pandemic period, we have priced well below value with preapproval supply agreements mostly to governments.”

Bancel said Moderna agrees with public health experts who say vaccinations and boosters with COVID-19 vaccines will be necessary “for many years to come,” adding that he believes the company has a responsibility to price the vaccine with global access in mind during the crisis.

The company recently launched a large-scale phase 3 trial of mRNA-1273 to find out if it can  prevent symptomatic COVID-19 after two doses. The study is being run with support from the NIH’s Institute of Allergy and Infectious Diseases (NIAID) and HHS’ Biomedical Advanced Research and Development Authority (BARDA), which has awarded the company contracts worth $955 million.

Moderna expects to be able to produce one billion doses of the vaccine next year (DID, July 28). — James Miessler